State of Alaska Department of Revenue Reduces Position in ICU Medical, Inc. (NASDAQ:ICUI)

State of Alaska Department of Revenue lessened its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 0.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 13,856 shares of the medical instruments supplier’s stock after selling 82 shares during the quarter. State of Alaska Department of Revenue’s holdings in ICU Medical were worth $2,150,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ICUI. FMR LLC boosted its holdings in shares of ICU Medical by 2,676.6% in the third quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock valued at $18,968,000 after purchasing an additional 100,345 shares during the period. State Street Corp boosted its holdings in shares of ICU Medical by 9.3% in the third quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after purchasing an additional 77,506 shares during the period. Geode Capital Management LLC boosted its holdings in shares of ICU Medical by 9.6% in the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock valued at $99,687,000 after purchasing an additional 48,106 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of ICU Medical by 10.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after purchasing an additional 27,927 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after purchasing an additional 25,031 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analysts Set New Price Targets

ICUI has been the subject of a number of analyst reports. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. KeyCorp upped their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Finally, Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and an average price target of $199.67.

ICU Medical Stock Performance

Shares of ICUI stock opened at $159.78 on Tuesday. The business’s fifty day simple moving average is $160.70 and its 200-day simple moving average is $164.00. The company has a market cap of $3.91 billion, a PE ratio of -34.96 and a beta of 0.63. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12-month low of $93.36 and a 12-month high of $196.26.

Insider Activity at ICU Medical

In related news, COO Christian B. Voigtlander sold 1,962 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $169.08, for a total value of $331,734.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 972 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the transaction, the director now directly owns 5,037 shares in the company, valued at approximately $796,400.07. The trade was a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 17,737 shares of company stock valued at $2,879,752 in the last ninety days. Company insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.